News
The U.S. Food and Drug Administration has granted approval to Empaveli as the primary treatment for C3 glomerulopathy .The drug has received approval for patients over 12 years and above who work to ...
HealthDay on MSN23h
FDA Approves Empaveli for Rare Kidney DiseasesThe U.S. Food and Drug Administration has approved Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback